J9

• Background:

  J9, in combination with dexamethasone inhibits cell growth in T-cell acute lymphoblastic leukemia (T-ALL) through the upregulation of the glucocorticoid receptor. Patients can develop glucocorticoid resistance rendering the treatment ineffective. J9 and its mechanism of action provides a useful strategy for overcoming the resistance. The EC50 of J9 in combination with dexamethasone is 28 uM. J9 alone was less toxic.

• Description:

  Glucocorticoid resistance inhibitor

• Product Name Alternative:

  4-cyclopropyl-5- (pyridin-4-yl) pyrimidin-2-amine

• UNSPSC:

  41116105

• Type:

  Inhibitor

• Source:

  Synthetic

• Field of Research:

  Cancer | Cell Signaling | Epigenetics and Nuclear Signaling

• Purity:

  99.9%

• Weight:

  0.01

• Format:

  White Solid

• Solubility:

  Soluble in CDCI3

• Molecular Formula:

  C12H12N4

• Molecular Weight:

  212.26

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1. Cantley A.M., et al. (2014) ACS Medicinal Chemistry Letters 5.7: 754-759.